Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for Intermittent Prevention of Menstrual Migraine
NCT06641466Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Mar 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of rimegepant in menstrual migraine, sponsored by Pfizer. Started Mar 2025; status: recruiting.
02
Drugs
rimegepant
03
Conditions
menstrual migraine
Beyond the preview
Go deeper on NCT06641466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06641466.